Company: TXG
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001770787-25-000013
Chunk: 133

Company: 10x Genomics, Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 7
Chunk 133
---
 31, 2023 compared to the year ended December 31, 2022, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023.

Year Ended December 31,(in thousands)202420232022Revenue$610,785 $618,727 $516,409 Cost of revenue196,303 209,414 120,386 Gross profit414,482 409,313 396,023 Operating expenses:Research and development264,698 270,332 265,667 In-process research and development— 60,980 — Selling, general and administrative344,343 343,330 298,300 Total operating expenses609,041 674,642 563,967 Loss from operations(194,559)(265,329)(167,944)Other income (expense):Interest income18,448 16,906 6,647 Interest expense(4)(33)(476)Other expense, net(1,585)(307)(198)Total other income16,859 16,566 5,973 Loss before provision for income taxes(177,700)(248,763)(161,971)Provision for income taxes4,927 6,336 4,029 Net loss$(182,627)$(255,099)$(166,000)

67

Revenue

Year Ended December 31,Change20242023$%InstrumentsChromium$35,212 $47,866 $(12,654)(26)%Spatial57,503 75,605 (18,102)(24)%Total instruments revenue92,715 123,471 (30,756)(25)%ConsumablesChromium372,308 420,316 (48,008)(11)%Spatial121,124 59,237 61,887 104 %Total consumables revenue493,432 479,553 13,879 3 %Services24,638 15,703 8,935 57 %Total revenue$610,785 $618,727 $(7,942)(1)%

Revenue decreased $7.9 million, or 1%, for the year ended December 31, 2024 as compared to the year ended December 31, 2023. Instruments revenue